文献速递精神分裂症与精神病性障碍物质与行为成瘾

伴或不伴大麻暴露的首发精神病认知、电生理与行为表现

Cognitive, Electrophysiological, and Behavioral Presentation of First-Episode Psychosis With or Without Cannabis Exposure.
PubMed 文献 · Am J Psychiatry · 2026-06-03

该前瞻性研究比较了66例伴大麻暴露(CAP)与53例不伴大麻暴露(NCAP)的男性首发精神病患者,在入院时及4周标准化住院治疗后评估认知、脑电与症状。CAP组认知改善更明显、阴性症状更轻、情绪症状更重,随访中恢复使用大麻与复发相关。

要点

  • CAP组认知测试表现显著改善而NCAP组无改善,入院时两组无差异。
  • CAP组入院时脑电功率谱密度指数更高,阴性及总分更低,抑郁和躁狂症状更重。
  • 随访16例CAP中10例恢复大麻后因精神病加重再住院,保持戒断者复发罕见。

核心结论

  • 伴大麻暴露的首发精神病患者较不伴暴露者认知功能更好、皮层兴奋/抑制平衡更低、阴性症状更轻、情绪症状更重。
  • 恢复使用大麻与精神病复发相关,提示大麻在疾病复发中的作用。
  • 结果提示大麻相关精神病可能是首发精神病的一个独特亚型。

研究设计与样本

  • 前瞻性研究,纳入因新发精神病住院的男性,伴确认大麻暴露者66例(CAP),不伴暴露者53例(NCAP)。
  • 在入院时及4周标准化住院治疗后评估认知测验、脑电图及症状量表。

主要发现

  • CAP组认知测试表现显著改善而NCAP组无改善,尽管入院时两组无差异。
  • 入院时CAP组较NCAP组脑电功率谱密度指数显著更高,作为皮层兴奋/抑制平衡的代理指标。
  • 入院时CAP组PANSS阴性及总分更低,但CDRS抑郁和YMRS躁狂症状更重。
  • 治疗对两组精神病症状均有改善,CAP组情绪症状改善更大。
  • 随访16例CAP参与者中,10例恢复大麻使用后因精神病加重再住院,保持戒断者复发罕见。

临床怎么用

  • 对首发精神病患者应评估大麻使用情况,伴暴露者可能表现为更轻的阴性症状和更重的情绪症状。
  • 对伴大麻暴露的首发精神病患者,应强调戒断大麻以降低复发风险。
  • 治疗随访中需关注情绪症状的改善及大麻恢复使用导致的复发。

局限性

  • 仅纳入男性住院患者,结果外推需谨慎。
  • 随访数据仅16例CAP参与者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cannabis use is a known risk factor for psychosis, but it remains unclear whether cannabis-associated psychosis (CAP) differs meaningfully from non-cannabis-associated psychosis (NCAP) in clinical presentation, biology, or illness course. The objective of this study was to characterize the presentation and course of first-episode psychosis with and without cannabis exposure. METHODS: In this prospective study, males hospitalized for new-onset psychosis with confirmed cannabis exposure (CAP; N=66) were compared with those without cannabis exposure (NCAP; N=53). Participants were assessed at admission and after 4 weeks of standardized inpatient treatment, using cognitive tests (CogState Schizophrenia Battery, Hopkins Verbal Learning Test), electroencephalography (EEG), and symptom scales (Positive and Negative Syndrome Scale [PANSS], Calgary Depression Rating Scale [CDRS], Young Mania Rating Scale [YMRS]). RESULTS: Cognitive test performance significantly improved in the CAP group but not in the NCAP group, despite the absence of group differences at the time of admission. At admission, relative to the NCAP group, the CAP group had significantly higher power spectral density exponent in the EEG, a proxy index of cortical excitatory/inhibitory (E/I) balance. CAP participants presented with lower PANSS negative and total scores but greater depressive (CDRS) and manic (YMRS) symptoms at admission. Psychosis symptoms improved with treatment in both groups, but the CAP group experienced greater improvement in mood symptoms. Follow-up data were available for 16 CAP participants; 10 were rehospitalized for psychosis exacerbation after resuming cannabis use, whereas relapse was rare among those who remained abstinent. CONCLUSIONS: Relative to the NCAP group, the CAP group exhibited better cognitive function, lower cortical E/I balance, lesser negative symptoms, and greater mood symptoms. Cannabis resumption was associated with relapse, highlighting its role in illness recurrence. Together, these results raise the possibility that cannabis-associated psychosis is a distinct subtype of first-episode psychosis. Given the increasing rates of psychosis related to cannabis, further studies are needed to examine its long-term trajectory and refine treatment approaches.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. D'Souza DC, Cortes-Briones J, Raj J, et al. Cognitive, Electrophysiological, and Behavioral Presentation of First-Episode Psychosis With or Without Cannabis Exposure. Am J Psychiatry. 2026. PMID: 42231079. doi:10.1176/appi.ajp.20250726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。